接种后不良事件与荷兰后续新冠加强针接种的关联
本研究基于VASCO前瞻性队列,纳入2022-2024年符合加强接种条件者,分析接种后不良事件(AE)与次年的再接种关联。结果显示,2022年发生全身性AE者2023年再接种几率较低(OR 0.84),且随严重程度和持续时间增加而下降;2024年再接种呈类似关联。
要点
- 全身性AE与次年加强针再接种几率降低相关(OR 0.84)。
- 严重全身性AE(OR 0.45)和严重局部AE(OR 0.38)与再接种几率降低相关。
- 因AE就医者再接种几率降低(OR 0.50)。
核心结论
- 经历全身性AE后,后续新冠加强针接种可能性降低,尤其是严重或持续时间长时。
- 严重局部AE也与后续接种率降低相关。
研究设计与样本
- 基于VASCO前瞻性队列,纳入2022-2024年符合加强接种条件者。
- 2022年和2023年分别有11,010和14,824名参与者完成接种后一个月AE问卷。
- 采用逻辑回归分析AE发生、严重程度和持续时间与次年再接种的关联,调整人口学因素和既往SARS-CoV-2感染。
主要发现
- 2022年及2023年接种者中,分别有73.7%和87.0%在后续年份再接种。
- 2022年全身性AE与2023年再接种几率降低相关(OR 0.84 [95%CI 0.76-0.93])。
- 全身性AE严重程度为中度(OR 0.79 [0.66-0.94])和重度(OR 0.45 [0.34-0.60])及持续时间>5天(OR 0.72 [0.54-0.95])与再接种几率降低相关。
- 严重局部AE(OR 0.38 [0.23-0.60])和因AE就医(OR 0.50 [0.34-0.73])与接种率降低相关。
- 2024年再接种观察到类似关联。
临床怎么用
- 在疫苗接种沟通策略中应关注并回应受种者经历的AE,可能有助于提高后续接种率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: This study aimed to assess whether the occurrence, severity, and duration of AE following COVID-19 booster vaccination were associated with subsequent booster uptake during the 2022-2024 autumn booster campaigns in the Netherlands. METHODS: We included participants from the Vaccine Study COVID-19 (VASCO), an ongoing prospective cohort study, who were eligible for booster vaccination in 2022-2024. Participants completed a questionnaire on AE one month after booster vaccination. Logistic regression was performed to assess the association between the occurrence, severity, and duration of local and systemic AE, and revaccination during the subsequent year. We adjusted for demographics and prior SARS-CoV-2 infection. RESULTS: In 2022 and 2023, 11,010 and 14,824 participants were vaccinated and completed the AE questionnaire. Of these, 73.7% and 87.0% were revaccinated in subsequent years. The occurrence of systemic AE in 2022 was associated with a lower odds of revaccination in 2023 (OR: 0.84 [95%CI, 0.76-0.93]). The likelihood of revaccination declined with increasing severity- moderate (0.79 [0.66-0.94]) and severe AE (0.45 [0.34-0.60]) - and longer duration (>5 days: 0.72 [0.54-0.95]) of systemic AE. Also, severe local AE (0.38 [0.23-0.60]) and seeking medical care for AE (0.50 [0.34-0.73]) were associated with reduced vaccination uptake. Similar associations were observed for revaccination in 2024. CONCLUSION: This study found a lower likelihood of subsequent COVID-19 booster uptake after experiencing systemic AE, particularly when severe or prolonged, or when experiencing a severe local AE. These findings underscore the need to address experienced AE in communication strategies, as this may influence the success of vaccination campaigns.
引用
- Huiberts AJ, Smits MMJ, Hoeve CE, et al. Association between post-vaccination adverse events and subsequent COVID-19 booster uptake in the Netherlands. Vaccine. 2026. PMID: 42603508. doi:10.1016/j.vaccine.2026.129043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。